https://www.live-feeds.com/feed/us-fda-approves-lilly-s-mounjaro-to-reduce-cardiovascular-riskContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/us-fda-approves-lilly-s-mounjaro-to-reduce-cardiovascular-riskhttps://www.live-feeds.com/feed/us-fda-approves-lilly-s-mounjaro-to-reduce-cardiovascular-risk#u52613Mon, 31 Aug 2026 01:47:07 +0000The US FDA has approved Eli Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. This expands Mounjaro's use beyond blood sugar control to include reduction of cardiovascular events in at-risk patients. Mounjaro is the first dual GIP and GLP-1 receptor agonist to gain this cardiovascular risk reduction indication.Why it mattersThis approval increases Eli Lilly's addressable patient pool and affects its competitive position in diabetes and cardiovascular disease treatment. Mounjaro's expanded use comes after previous approvals for bloo